MIRA — Mira Pharmaceuticals Share Price
Last trade - 00:00- $15.79m
- $12.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.18 | ||
| Price to Tang. Book | 7.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -364.47% | ||
| Return on Equity | -238.9% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial. It is for patients suffering from neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD). MIRA-55 is a preclinical-stage investigational drug designed to support cognitive function and enhance memory. It is for the treatment of patients experiencing cognitive decline, including those with early neurodegenerative conditions.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 3rd, 2020
- Public Since
- August 3rd, 2023
- No. of Shareholders
- 55
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 16,813,654
- Address
- 1200 Brickell Avenue, Suite 1950 #1183, MIAMI, 33131
- Web
- https://mirapharmaceuticals.com/
- Phone
- +1 8133695150
- Auditors
- Cherry Bekaert LLP
Similar to MIRA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 22:04 UTC, shares in Mira Pharmaceuticals are trading at $0.94. This share price information is delayed by 15 minutes.
Shares in Mira Pharmaceuticals last closed at $0.94 and the price had moved by +15.94% over the past 365 days. In terms of relative price strength the Mira Pharmaceuticals share price has outperformed the S&P500 Index by +9.01% over the past year.
The overall consensus recommendation for Mira Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMira Pharmaceuticals does not currently pay a dividend.
Mira Pharmaceuticals does not currently pay a dividend.
Mira Pharmaceuticals does not currently pay a dividend.
To buy shares in Mira Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.94, shares in Mira Pharmaceuticals had a market capitalisation of $15.79m.
Here are the trading details for Mira Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MIRA
Based on an overall assessment of its quality, value and momentum Mira Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mira Pharmaceuticals is $14.38. That is 1431.58% above the last closing price of $0.94.
Analysts covering Mira Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.54 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mira Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -5.42%.
As of the last closing price of $0.94, shares in Mira Pharmaceuticals were trading -29.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mira Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Mira Pharmaceuticals' directors